Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07220876 · ClinicalTrials.gov registry record · NA
Safety and Effectiveness of the VisiPlate Aqueous Shunt in Patients With Refractory Open-Angle Glaucoma
A NA study of Open Angle Glaucoma (OAG), sponsored by Avisi Technologies.
- Recruiting
- Registry status
- NA
- Development phase
- 165
- Enrollment target
- 12
- Study locations
NCT07220876 is a NA study of Open Angle Glaucoma (OAG) that is actively recruiting participants, run by Avisi Technologies. The registered enrollment target is 165 participants, above the 35-participant average among 5 other Open Angle Glaucoma (OAG) trials with a reported enrollment target (371% higher). The trial reports 12 study locations across 8 states.
The verdict
NCT07220876, a NA study of Open Angle Glaucoma (OAG), is actively recruiting participants, sponsored by Avisi Technologies.
- RECRUITING
- Registry status
- NA
- Development phase
- 165 participants
- Enrollment target
- 12
- Study locations
Study Summary
A Prospective, Multicenter, Single-Arm, Open-Label Clinical Trial
Conditions Studied
Interventions
- DEVICE VisiPlate Glaucoma Implant
Study Locations (12)
Colorado
- ICON Eye Care - Grand Junction
- Mile High Eye Institute - Sheridan
Pennsylvania
- Scheie Eye Institute - Philadelphia
- Wills Eye Hospital - Philadelphia
Texas
- Glaucoma Associates of Texas - Dallas
- University of Texas Southwestern - Dallas
Other
- Lynette Venter - Bloemfontein
- Pretoria Eye Institute - Pretoria
Arizona
- Arizona Advanced Eye Research - Glendale
California
- Sacramento Eye Consultants - Sacramento
Ohio
- Cleveland Clinic- Cole Eye Institute - Cleveland
Wisconsin
- The Eye Centers of Racine & Kenosha - Kenosha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2025-11-07 |
| Est. Completion | 2027-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07220876
The ClinicalTrials.gov registry entry for NCT07220876 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 35-participant average among 5 other Open Angle Glaucoma (OAG) trials with a reported enrollment target (371% higher). The listed sponsor is Avisi Technologies, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Open Angle Glaucoma (OAG) appearing as the primary indexed condition, and to 1 intervention - of which VisiPlate Glaucoma Implant is the first listed.
NCT07220876 reports 12 study locations spanning 8 distinct geographic areas - top geographies include Colorado, Pennsylvania, Texas.
Frequently Asked Questions
What is clinical trial NCT07220876 about?
NCT07220876 is a clinical study titled "Safety and Effectiveness of the VisiPlate Aqueous Shunt in Patients With Refractory Open-Angle Glaucoma". A Prospective, Multicenter, Single-Arm, Open-Label Clinical Trial
What is the current status of trial NCT07220876?
This trial is currently recruiting. It is a NA study. The enrollment target is 165 participants. The study started on 2025-11-07. Estimated completion is 2027-10.
What conditions does trial NCT07220876 study?
This clinical trial studies the following conditions: Open Angle Glaucoma (OAG).
What interventions are being tested in trial NCT07220876?
The interventions under investigation include: VisiPlate Glaucoma Implant (DEVICE).
Who is sponsoring clinical trial NCT07220876?
This trial is sponsored by Avisi Technologies, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07220876 being conducted?
This trial has 12 study locations across Arizona, California, Colorado, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Open Angle Glaucoma (OAG)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
DSLT Performance in Treatment-naïve Patients With Newly Diagnosed Open Angle Glaucoma
RECRUITING
-
Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg
RECRUITING
-
Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)
RECRUITING · Phase 1
-
Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation
RECRUITING · Phase 2
-
Travoprost Five Day Posology Study
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.